These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34753066)

  • 1. A novel oral inhibitor for one-carbon metabolism and checkpoint kinase 1 inhibitor as a rational combination treatment for breast cancer.
    Lee J; Chen X; Wang Y; Nishimura T; Li M; Ishikawa S; Daikoku T; Kawai J; Tojo A; Gotoh N
    Biochem Biophys Res Commun; 2021 Dec; 584():7-14. PubMed ID: 34753066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications.
    Ju HQ; Lu YX; Chen DL; Zuo ZX; Liu ZX; Wu QN; Mo HY; Wang ZX; Wang DS; Pu HY; Zeng ZL; Li B; Xie D; Huang P; Hung MC; Chiao PJ; Xu RH
    J Natl Cancer Inst; 2019 Jun; 111(6):584-596. PubMed ID: 30534944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xanthine Derivatives Reveal an Allosteric Binding Site in Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2).
    Lee LC; Peng YH; Chang HH; Hsu T; Lu CT; Huang CH; Hsueh CC; Kung FC; Kuo CC; Jiaang WT; Wu SY
    J Med Chem; 2021 Aug; 64(15):11288-11301. PubMed ID: 34337952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate-mediated one-carbon metabolism: a targeting strategy in cancer therapy.
    Yang C; Zhang J; Liao M; Yang Y; Wang Y; Yuan Y; Ouyang L
    Drug Discov Today; 2021 Mar; 26(3):817-825. PubMed ID: 33316375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity.
    Kawai J; Toki T; Ota M; Inoue H; Takata Y; Asahi T; Suzuki M; Shimada T; Ono K; Suzuki K; Takaishi S; Ohki H; Matsui S; Tsutsumi S; Hirota Y; Nakayama K
    J Med Chem; 2019 Nov; 62(22):10204-10220. PubMed ID: 31638799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion.
    Lin H; Huang B; Wang H; Liu X; Hong Y; Qiu S; Zheng J
    Cell Physiol Biochem; 2018; 51(2):991-1000. PubMed ID: 30466107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.
    Shang M; Yang H; Yang R; Chen T; Fu Y; Li Y; Fang X; Zhang K; Zhang J; Li H; Cao X; Gu J; Xiao J; Zhang Q; Liu X; Yu Q; Wang T
    Nat Commun; 2021 Mar; 12(1):1940. PubMed ID: 33782411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2.
    Nishimura T; Nakata A; Chen X; Nishi K; Meguro-Horike M; Sasaki S; Kita K; Horike SI; Saitoh K; Kato K; Igarashi K; Murayama T; Kohno S; Takahashi C; Mukaida N; Yano S; Soga T; Tojo A; Gotoh N
    Oncogene; 2019 Apr; 38(14):2464-2481. PubMed ID: 30532069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selectivity analysis of diaminopyrimidine-based inhibitors of MTHFD1, MTHFD2 and MTHFD2L.
    Jha V; Eriksson LA
    Sci Rep; 2024 Sep; 14(1):21073. PubMed ID: 39256448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
    Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation.
    Choi C; Cho WK; Park S; Shin SW; Park W; Kim H; Choi DH
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target.
    Grellety T; Callens C; Richard E; Briaux A; Vélasco V; Pulido M; Gonçalves A; Gestraud P; MacGrogan G; Bonnefoi H; Cardinaud B
    Clin Cancer Res; 2019 Jan; 25(2):856-867. PubMed ID: 30352905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial targeting of MTHFD2 and PAICS in purine synthesis as a novel therapeutic strategy.
    Cheung CHY; Hsu CL; Tsuei CY; Kuo TT; Huang CT; Hsu WM; Chung YH; Wu HY; Hsu CC; Huang HC; Juan HF
    Cell Death Dis; 2019 Oct; 10(11):786. PubMed ID: 31624245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage.
    Li G; Wu J; Li L; Jiang P
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34244426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MTHFD2 promotes ovarian cancer growth and metastasis via activation of the STAT3 signaling pathway.
    Li Q; Yang F; Shi X; Bian S; Shen F; Wu Y; Zhu C; Fu F; Wang J; Zhou J; Chen Y
    FEBS Open Bio; 2021 Oct; 11(10):2845-2857. PubMed ID: 34231329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTHFD2 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating AKT/GSK-3β/β-catenin signalling.
    Shi Y; Xu Y; Yao J; Yan C; Su H; Zhang X; Chen E; Ying K
    J Cell Mol Med; 2021 Jul; 25(14):7013-7027. PubMed ID: 34121323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
    Satriyo PB; Su CM; Ong JR; Huang WC; Fong IH; Lin CC; Aryandono T; Haryana SM; Deng L; Huang CC; Tzeng YM; Chao TY; Liu HW; Yeh CT
    Toxicol Appl Pharmacol; 2021 Jul; 422():115493. PubMed ID: 33727089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin.
    Zhu H; Rao Z; Yuan S; You J; Hong C; He Q; Yang B; Du C; Cao J
    Eur J Pharmacol; 2021 Oct; 908():174366. PubMed ID: 34314706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
    Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
    J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
    Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
    Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.